APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostate Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Prostate Cancer Drugs Industry Research Report 2026

20 December 2025144 pages

Choose your research edition.

Industry ResearchProstate Cancer Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostate Cancer Drugs Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Prostate Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostate Cancer Drugs Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostate Cancer Drugs Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Prostate Cancer Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Prostate Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Prostate Cancer Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Prostate Cancer Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Prostate Cancer Drugs include Takeda Pharmaceuticals, Teva Pharmaceutical, Sanofi, Johnson & Johnson, Novartis, Merck Group, GlaxoSmithKline, Amgen and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Prostate Cancer Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Prostate Cancer Drugs Market by Company

Takeda Pharmaceuticals

Teva Pharmaceutical

Sanofi

Johnson & Johnson

Novartis

Merck Group

GlaxoSmithKline

Amgen

AbbVie

Tokai Pharmaceuticals

Spectrum Pharmaceuticals

Northwest Biotherapeutics

Janssen Pharmaceuticals

Foresee Pharmaceuticals

Ferring Pharmaceutical

Endo Pharmaceuticals

Boehringer Ingelheim

BMS

Bayer HealthCare

Astra Zeneca

Astellas Pharma

Prostate Cancer Drugs Segment by Type

Targeted Therapy

Chemotherapy

Hormonal Therapy

Immunotherapy

Prostate Cancer Drugs Segment by Application

Clinics

Hospitals

Others

Prostate Cancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Prostate Cancer Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Prostate Cancer Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Prostate Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Prostate Cancer Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Prostate Cancer Drugs Sales (K Tons) of Manufacturers (2021-2026) Table 7. Global Prostate Cancer Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Prostate Cancer Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Prostate Cancer Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Prostate Cancer Drugs Average Price (US$/Ton) of Manufacturers (2021-2026) Table 11. Global Prostate Cancer Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Prostate Cancer Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Prostate Cancer Drugs, Product Type & Application Table 14. Global Prostate Cancer Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Prostate Cancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Pharmaceuticals Company Information Table 19. Takeda Pharmaceuticals Business Overview Table 20. Takeda Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 21. Takeda Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 22. Takeda Pharmaceuticals Recent Developments Table 23. Teva Pharmaceutical Company Information Table 24. Teva Pharmaceutical Business Overview Table 25. Teva Pharmaceutical Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 26. Teva Pharmaceutical Prostate Cancer Drugs Product Portfolio Table 27. Teva Pharmaceutical Recent Developments Table 28. Sanofi Company Information Table 29. Sanofi Business Overview Table 30. Sanofi Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 31. Sanofi Prostate Cancer Drugs Product Portfolio Table 32. Sanofi Recent Developments Table 33. Johnson & Johnson Company Information Table 34. Johnson & Johnson Business Overview Table 35. Johnson & Johnson Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 36. Johnson & Johnson Prostate Cancer Drugs Product Portfolio Table 37. Johnson & Johnson Recent Developments Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 41. Novartis Prostate Cancer Drugs Product Portfolio Table 42. Novartis Recent Developments Table 43. Merck Group Company Information Table 44. Merck Group Business Overview Table 45. Merck Group Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 46. Merck Group Prostate Cancer Drugs Product Portfolio Table 47. Merck Group Recent Developments Table 48. GlaxoSmithKline Company Information Table 49. GlaxoSmithKline Business Overview Table 50. GlaxoSmithKline Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 51. GlaxoSmithKline Prostate Cancer Drugs Product Portfolio Table 52. GlaxoSmithKline Recent Developments Table 53. Amgen Company Information Table 54. Amgen Business Overview Table 55. Amgen Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 56. Amgen Prostate Cancer Drugs Product Portfolio Table 57. Amgen Recent Developments Table 58. AbbVie Company Information Table 59. AbbVie Business Overview Table 60. AbbVie Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 61. AbbVie Prostate Cancer Drugs Product Portfolio Table 62. AbbVie Recent Developments Table 63. Tokai Pharmaceuticals Company Information Table 64. Tokai Pharmaceuticals Business Overview Table 65. Tokai Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 66. Tokai Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 67. Tokai Pharmaceuticals Recent Developments Table 68. Spectrum Pharmaceuticals Company Information Table 69. Spectrum Pharmaceuticals Business Overview Table 70. Spectrum Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 71. Spectrum Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 72. Spectrum Pharmaceuticals Recent Developments Table 73. Northwest Biotherapeutics Company Information Table 74. Northwest Biotherapeutics Business Overview Table 75. Northwest Biotherapeutics Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 76. Northwest Biotherapeutics Prostate Cancer Drugs Product Portfolio Table 77. Northwest Biotherapeutics Recent Developments Table 78. Janssen Pharmaceuticals Company Information Table 79. Janssen Pharmaceuticals Business Overview Table 80. Janssen Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 81. Janssen Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 82. Janssen Pharmaceuticals Recent Developments Table 83. Foresee Pharmaceuticals Company Information Table 84. Foresee Pharmaceuticals Business Overview Table 85. Foresee Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 86. Foresee Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 87. Foresee Pharmaceuticals Recent Developments Table 88. Ferring Pharmaceutical Company Information Table 89. Ferring Pharmaceutical Business Overview Table 90. Ferring Pharmaceutical Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 91. Ferring Pharmaceutical Prostate Cancer Drugs Product Portfolio Table 92. Ferring Pharmaceutical Recent Developments Table 93. Endo Pharmaceuticals Company Information Table 94. Endo Pharmaceuticals Business Overview Table 95. Endo Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 96. Endo Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 97. Endo Pharmaceuticals Recent Developments Table 98. Boehringer Ingelheim Company Information Table 99. Boehringer Ingelheim Business Overview Table 100. Boehringer Ingelheim Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 101. Boehringer Ingelheim Prostate Cancer Drugs Product Portfolio Table 102. Boehringer Ingelheim Recent Developments Table 103. BMS Company Information Table 104. BMS Business Overview Table 105. BMS Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 106. BMS Prostate Cancer Drugs Product Portfolio Table 107. BMS Recent Developments Table 108. Bayer HealthCare Company Information Table 109. Bayer HealthCare Business Overview Table 110. Bayer HealthCare Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 111. Bayer HealthCare Prostate Cancer Drugs Product Portfolio Table 112. Bayer HealthCare Recent Developments Table 113. Astra Zeneca Company Information Table 114. Astra Zeneca Business Overview Table 115. Astra Zeneca Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 116. Astra Zeneca Prostate Cancer Drugs Product Portfolio Table 117. Astra Zeneca Recent Developments Table 118. Astellas Pharma Company Information Table 119. Astellas Pharma Business Overview Table 120. Astellas Pharma Prostate Cancer Drugs Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 121. Astellas Pharma Prostate Cancer Drugs Product Portfolio Table 122. Astellas Pharma Recent Developments Table 123. Global Prostate Cancer Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 124. Global Prostate Cancer Drugs Sales by Region (2021-2026) & (K Tons) Table 125. Global Prostate Cancer Drugs Sales Market Share by Region (2021-2026) Table 126. Global Prostate Cancer Drugs Sales by Region (2027-2032) & (K Tons) Table 127. Global Prostate Cancer Drugs Sales Market Share by Region (2027-2032) Table 128. Global Prostate Cancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 129. Global Prostate Cancer Drugs Revenue Market Share by Region (2021-2026) Table 130. Global Prostate Cancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 131. Global Prostate Cancer Drugs Revenue Market Share by Region (2027-2032) Table 132. North America Prostate Cancer Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. North America Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 134. North America Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 135. North America Prostate Cancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. North America Prostate Cancer Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Europe Prostate Cancer Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Europe Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 139. Europe Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 140. Europe Prostate Cancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. Europe Prostate Cancer Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Asia Pacific Prostate Cancer Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Asia Pacific Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 144. Asia Pacific Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 145. Asia Pacific Prostate Cancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. Asia Pacific Prostate Cancer Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. South America Prostate Cancer Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. South America Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 149. South America Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 150. South America Prostate Cancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 151. South America Prostate Cancer Drugs Revenue by Country (2027-2032) & (US$ Million) Table 152. Middle East and Africa Prostate Cancer Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Middle East and Africa Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 154. Middle East and Africa Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 155. Middle East and Africa Prostate Cancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Prostate Cancer Drugs Revenue by Country (2027-2032) & (US$ Million) Table 157. Global Prostate Cancer Drugs Sales by Type (2021-2026) & (K Tons) Table 158. Global Prostate Cancer Drugs Sales by Type (2027-2032) & (K Tons) Table 159. Global Prostate Cancer Drugs Sales Market Share by Type (2021-2026) Table 160. Global Prostate Cancer Drugs Sales Market Share by Type (2027-2032) Table 161. Global Prostate Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 162. Global Prostate Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 163. Global Prostate Cancer Drugs Revenue Market Share by Type (2021-2026) Table 164. Global Prostate Cancer Drugs Revenue Market Share by Type (2027-2032) Table 165. Global Prostate Cancer Drugs Price by Type (2021-2026) & (US$/Ton) Table 166. Global Prostate Cancer Drugs Price by Type (2027-2032) & (US$/Ton) Table 167. Global Prostate Cancer Drugs Sales by Application (2021-2026) & (K Tons) Table 168. Global Prostate Cancer Drugs Sales by Application (2027-2032) & (K Tons) Table 169. Global Prostate Cancer Drugs Sales Market Share by Application (2021-2026) Table 170. Global Prostate Cancer Drugs Sales Market Share by Application (2027-2032) Table 171. Global Prostate Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 172. Global Prostate Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 173. Global Prostate Cancer Drugs Revenue Market Share by Application (2021-2026) Table 174. Global Prostate Cancer Drugs Revenue Market Share by Application (2027-2032) Table 175. Global Prostate Cancer Drugs Price by Application (2021-2026) & (US$/Ton) Table 176. Global Prostate Cancer Drugs Price by Application (2027-2032) & (US$/Ton) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Prostate Cancer Drugs Distributors List Table 180. Prostate Cancer Drugs Customers List Table 181. Prostate Cancer Drugs Industry Trends Table 182. Prostate Cancer Drugs Industry Drivers Table 183. Prostate Cancer Drugs Industry Restraints Table 184. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Prostate Cancer Drugs Product Image Figure 5. Global Prostate Cancer Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Prostate Cancer Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Prostate Cancer Drugs Sales (2021-2032) & (K Tons) Figure 8. Global Prostate Cancer Drugs Average Price (US$/Ton) & (2021-2032) Figure 9. Targeted Therapy Product Image Figure 10. Chemotherapy Product Image Figure 11. Hormonal Therapy Product Image Figure 12. Immunotherapy Product Image Figure 13. Clinics Product Image Figure 14. Hospitals Product Image Figure 15. Others Product Image Figure 16. Global Prostate Cancer Drugs Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Prostate Cancer Drugs, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Prostate Cancer Drugs Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Prostate Cancer Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Prostate Cancer Drugs Sales by Region in 2025 Figure 22. Global Prostate Cancer Drugs Revenue by Region in 2025 Figure 23. North America Prostate Cancer Drugs Market Size by Country in 2025 Figure 24. North America Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 25. North America Prostate Cancer Drugs Revenue Market Share by Country (2021-2032) Figure 26. United States Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Prostate Cancer Drugs Market Size by Country in 2025 Figure 29. Europe Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 30. Europe Prostate Cancer Drugs Revenue Market Share by Country (2021-2032) Figure 31. Germany Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Nordic Countries Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Prostate Cancer Drugs Market Size by Country in 2025 Figure 38. Asia Pacific Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Prostate Cancer Drugs Revenue Market Share by Country (2021-2032) Figure 40. China Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Prostate Cancer Drugs Market Size by Country in 2025 Figure 49. South America Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 50. South America Prostate Cancer Drugs Revenue Market Share by Country (2021-2032) Figure 51. Mexico Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Colombia Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Middle East and Africa Prostate Cancer Drugs Market Size by Country in 2025 Figure 56. Middle East and Africa Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 57. Middle East and Africa Prostate Cancer Drugs Revenue Market Share by Country (2021-2032) Figure 58. Turkey Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. UAE Prostate Cancer Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Global Prostate Cancer Drugs Sales Market Share by Type (2021-2032) Figure 62. Global Prostate Cancer Drugs Revenue Market Share by Type (2021-2032) Figure 63. Global Prostate Cancer Drugs Price (US$/Ton) by Type (2021-2032) Figure 64. Global Prostate Cancer Drugs Sales Market Share by Application (2021-2032) Figure 65. Global Prostate Cancer Drugs Revenue Market Share by Application (2021-2032) Figure 66. Global Prostate Cancer Drugs Price (US$/Ton) by Application (2021-2032) Figure 67. Prostate Cancer Drugs Value Chain Figure 68. Prostate Cancer Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Prostate Cancer Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
Applications
  • Clinics
  • Hospitals
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck Group
  • GlaxoSmithKline
  • Amgen
  • AbbVie
  • Tokai Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Northwest Biotherapeutics
  • Janssen Pharmaceuticals
  • Foresee Pharmaceuticals
  • Ferring Pharmaceutical
  • Endo Pharmaceuticals
  • Boehringer Ingelheim
  • BMS
  • Bayer HealthCare
  • Astra Zeneca
  • Astellas Pharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Prostate Cancer Drugs Market Size (2021-2032)
  4. 2.2.2 Global Prostate Cancer Drugs Sales (2021-2032)
  5. 2.2.3 Global Prostate Cancer Drugs Market Average Price (2021-2032)
  6. 2.3 Prostate Cancer Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Targeted Therapy
  9. 2.3.3 Chemotherapy
  10. 2.3.4 Hormonal Therapy
  11. 2.3.5 Immunotherapy
  12. 2.4 Prostate Cancer Drugs by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Clinics
  15. 2.4.3 Hospitals
  16. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Prostate Cancer Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Prostate Cancer Drugs Sales (K Tons) of Manufacturers (2021-2026)
  3. 3.3 Global Prostate Cancer Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Prostate Cancer Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Prostate Cancer Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Prostate Cancer Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Prostate Cancer Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Prostate Cancer Drugs, Established Date
  9. 3.9 Global Prostate Cancer Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda Pharmaceuticals
  2. 4.1.1 Takeda Pharmaceuticals Company Information
  3. 4.1.2 Takeda Pharmaceuticals Business Overview
  4. 4.1.3 Takeda Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  6. 4.1.5 Takeda Pharmaceuticals Recent Developments
  7. 4.2 Teva Pharmaceutical
  8. 4.2.1 Teva Pharmaceutical Company Information
  9. 4.2.2 Teva Pharmaceutical Business Overview
  10. 4.2.3 Teva Pharmaceutical Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Teva Pharmaceutical Prostate Cancer Drugs Product Portfolio
  12. 4.2.5 Teva Pharmaceutical Recent Developments
  13. 4.3 Sanofi
  14. 4.3.1 Sanofi Company Information
  15. 4.3.2 Sanofi Business Overview
  16. 4.3.3 Sanofi Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sanofi Prostate Cancer Drugs Product Portfolio
  18. 4.3.5 Sanofi Recent Developments
  19. 4.4 Johnson & Johnson
  20. 4.4.1 Johnson & Johnson Company Information
  21. 4.4.2 Johnson & Johnson Business Overview
  22. 4.4.3 Johnson & Johnson Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Johnson & Johnson Prostate Cancer Drugs Product Portfolio
  24. 4.4.5 Johnson & Johnson Recent Developments
  25. 4.5 Novartis
  26. 4.5.1 Novartis Company Information
  27. 4.5.2 Novartis Business Overview
  28. 4.5.3 Novartis Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novartis Prostate Cancer Drugs Product Portfolio
  30. 4.5.5 Novartis Recent Developments
  31. 4.6 Merck Group
  32. 4.6.1 Merck Group Company Information
  33. 4.6.2 Merck Group Business Overview
  34. 4.6.3 Merck Group Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Merck Group Prostate Cancer Drugs Product Portfolio
  36. 4.6.5 Merck Group Recent Developments
  37. 4.7 GlaxoSmithKline
  38. 4.7.1 GlaxoSmithKline Company Information
  39. 4.7.2 GlaxoSmithKline Business Overview
  40. 4.7.3 GlaxoSmithKline Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 GlaxoSmithKline Prostate Cancer Drugs Product Portfolio
  42. 4.7.5 GlaxoSmithKline Recent Developments
  43. 4.8 Amgen
  44. 4.8.1 Amgen Company Information
  45. 4.8.2 Amgen Business Overview
  46. 4.8.3 Amgen Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Amgen Prostate Cancer Drugs Product Portfolio
  48. 4.8.5 Amgen Recent Developments
  49. 4.9 AbbVie
  50. 4.9.1 AbbVie Company Information
  51. 4.9.2 AbbVie Business Overview
  52. 4.9.3 AbbVie Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AbbVie Prostate Cancer Drugs Product Portfolio
  54. 4.9.5 AbbVie Recent Developments
  55. 4.10 Tokai Pharmaceuticals
  56. 4.10.1 Tokai Pharmaceuticals Company Information
  57. 4.10.2 Tokai Pharmaceuticals Business Overview
  58. 4.10.3 Tokai Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Tokai Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  60. 4.10.5 Tokai Pharmaceuticals Recent Developments
  61. 4.11 Spectrum Pharmaceuticals
  62. 4.11.1 Spectrum Pharmaceuticals Company Information
  63. 4.11.2 Spectrum Pharmaceuticals Business Overview
  64. 4.11.3 Spectrum Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Spectrum Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  66. 4.11.5 Spectrum Pharmaceuticals Recent Developments
  67. 4.12 Northwest Biotherapeutics
  68. 4.12.1 Northwest Biotherapeutics Company Information
  69. 4.12.2 Northwest Biotherapeutics Business Overview
  70. 4.12.3 Northwest Biotherapeutics Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Northwest Biotherapeutics Prostate Cancer Drugs Product Portfolio
  72. 4.12.5 Northwest Biotherapeutics Recent Developments
  73. 4.13 Janssen Pharmaceuticals
  74. 4.13.1 Janssen Pharmaceuticals Company Information
  75. 4.13.2 Janssen Pharmaceuticals Business Overview
  76. 4.13.3 Janssen Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Janssen Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  78. 4.13.5 Janssen Pharmaceuticals Recent Developments
  79. 4.14 Foresee Pharmaceuticals
  80. 4.14.1 Foresee Pharmaceuticals Company Information
  81. 4.14.2 Foresee Pharmaceuticals Business Overview
  82. 4.14.3 Foresee Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Foresee Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  84. 4.14.5 Foresee Pharmaceuticals Recent Developments
  85. 4.15 Ferring Pharmaceutical
  86. 4.15.1 Ferring Pharmaceutical Company Information
  87. 4.15.2 Ferring Pharmaceutical Business Overview
  88. 4.15.3 Ferring Pharmaceutical Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Ferring Pharmaceutical Prostate Cancer Drugs Product Portfolio
  90. 4.15.5 Ferring Pharmaceutical Recent Developments
  91. 4.16 Endo Pharmaceuticals
  92. 4.16.1 Endo Pharmaceuticals Company Information
  93. 4.16.2 Endo Pharmaceuticals Business Overview
  94. 4.16.3 Endo Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Endo Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  96. 4.16.5 Endo Pharmaceuticals Recent Developments
  97. 4.17 Boehringer Ingelheim
  98. 4.17.1 Boehringer Ingelheim Company Information
  99. 4.17.2 Boehringer Ingelheim Business Overview
  100. 4.17.3 Boehringer Ingelheim Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Boehringer Ingelheim Prostate Cancer Drugs Product Portfolio
  102. 4.17.5 Boehringer Ingelheim Recent Developments
  103. 4.18 BMS
  104. 4.18.1 BMS Company Information
  105. 4.18.2 BMS Business Overview
  106. 4.18.3 BMS Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 BMS Prostate Cancer Drugs Product Portfolio
  108. 4.18.5 BMS Recent Developments
  109. 4.19 Bayer HealthCare
  110. 4.19.1 Bayer HealthCare Company Information
  111. 4.19.2 Bayer HealthCare Business Overview
  112. 4.19.3 Bayer HealthCare Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Bayer HealthCare Prostate Cancer Drugs Product Portfolio
  114. 4.19.5 Bayer HealthCare Recent Developments
  115. 4.20 Astra Zeneca
  116. 4.20.1 Astra Zeneca Company Information
  117. 4.20.2 Astra Zeneca Business Overview
  118. 4.20.3 Astra Zeneca Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Astra Zeneca Prostate Cancer Drugs Product Portfolio
  120. 4.20.5 Astra Zeneca Recent Developments
  121. 4.21 Astellas Pharma
  122. 4.21.1 Astellas Pharma Company Information
  123. 4.21.2 Astellas Pharma Business Overview
  124. 4.21.3 Astellas Pharma Prostate Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Astellas Pharma Prostate Cancer Drugs Product Portfolio
  126. 4.21.5 Astellas Pharma Recent Developments
5 Global Prostate Cancer Drugs Market Scenario by Region
  1. 5.1 Global Prostate Cancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Prostate Cancer Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Prostate Cancer Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Prostate Cancer Drugs Sales by Region: 2027-2032
  5. 5.3 Global Prostate Cancer Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Prostate Cancer Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Prostate Cancer Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Prostate Cancer Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Prostate Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Prostate Cancer Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Prostate Cancer Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Prostate Cancer Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Prostate Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Prostate Cancer Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Prostate Cancer Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Prostate Cancer Drugs Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Prostate Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Prostate Cancer Drugs Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Prostate Cancer Drugs Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Prostate Cancer Drugs Market Facts & Figures by Country
  36. 5.7.1 South America Prostate Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Prostate Cancer Drugs Sales by Country (2021-2032)
  38. 5.7.3 South America Prostate Cancer Drugs Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.7.7 Colombia
  43. 5.8 Middle East and Africa Prostate Cancer Drugs Market Facts & Figures by Country
  44. 5.8.1 Middle East and Africa Prostate Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
  45. 5.8.2 Middle East and Africa Prostate Cancer Drugs Sales by Country (2021-2032)
  46. 5.8.3 Middle East and Africa Prostate Cancer Drugs Revenue by Country (2021-2032)
  47. 5.8.4 Turkey
  48. 5.8.5 Saudi Arabia
  49. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Prostate Cancer Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Prostate Cancer Drugs Sales by Type (2021-2032) & (K Tons)
  3. 6.1.2 Global Prostate Cancer Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Prostate Cancer Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Prostate Cancer Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Prostate Cancer Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Prostate Cancer Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Prostate Cancer Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Prostate Cancer Drugs Sales by Application (2021-2032) & (K Tons)
  3. 7.1.2 Global Prostate Cancer Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Prostate Cancer Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Prostate Cancer Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Prostate Cancer Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Prostate Cancer Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Prostate Cancer Drugs Value Chain Analysis
  2. 8.1.1 Prostate Cancer Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Prostate Cancer Drugs Production Mode & Process
  5. 8.2 Prostate Cancer Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Prostate Cancer Drugs Distributors
  8. 8.2.3 Prostate Cancer Drugs Customers
9 Global Prostate Cancer Drugs Analyzing Market Dynamics
  1. 9.1 Prostate Cancer Drugs Industry Trends
  2. 9.2 Prostate Cancer Drugs Industry Drivers
  3. 9.3 Prostate Cancer Drugs Industry Opportunities and Challenges
  4. 9.4 Prostate Cancer Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst